BioCentury
ARTICLE | Finance

Revolution revamp

How Revolution’s SHP-2 inhibitor persuaded Nextech to back $56 million series B

April 27, 2018 3:05 PM UTC

Revolution Medicines Inc.’s pivot to cancer and preclinical proof-of-concept data for its lead program convinced Nextech Invest to lead the company’s $56 million series B round.

Fellow new investors Casdin Capital and Schroder Adveq and existing investors Third Rock Ventures and The Column Group also participated in the round, which closed on April 24. ...